Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1α in vitro and in vivo

Cancer Biology and Therapy

Volumn 14, Issue 11, 2013, Pages 1068-1073

  Yang, Xi ^a   Yang, Baixia ^a   Cai, Jing ^b   Zhang, Chi ^a   Zhang, Qu ^c   Xu, Liping ^a   Qin, Qin ^a   Zhu, Hongcheng ^a   Jianxin, Ma ^c   Tao, Guangzhou ^d   Cheng, Hongyan ^a   Sun, Xinchen ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG TUMOR HOSPITAL   (China)

^c Second People Hospital of Lianyungang   (China)

^d THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Berberine; Esophageal cancer; HIF 1 ; Hypoxia; Radiosensitivity

Indexed keywords

BERBERINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL GROWTH; CELL SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL HYPOXIA; CELL PROLIFERATION; DRUG EFFECT; ESOPHAGUS CANCER; ESOPHAGUS TUMOR; HIF-1Α; IN VITRO STUDY; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

BERBERINE; ESOPHAGEAL CANCER; HIF-1Α; HYPOXIA; RADIOSENSITIVITY;

ANIMALS; APOPTOSIS; BERBERINE; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIATION TOLERANCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890030504     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26426     Document Type: Article

References (20)

1. Shridhar R, Almhanna K, Meredith KL, Biagioli MC, Chuong MD, Cruz A, Hoffe SE. Radiation therapy and esophageal cancer. Cancer Control 2013; 20:97-110; PMID:23571700
2. Bayer C, Vaupel P. Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences. Strahlenther Onkol 2012; 188:616-27; PMID:22454045; http://dx.doi.org/10.1007/s00066-012-0085-4
3. Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther 2011; 12:908-14; PMID:22027557; http://dx.doi.org/10.4161/cbt. 12.10.17681
4. Moeller BJ, Dewhirst MW. HIF-1 and tumour radiosensitivity. Br J Cancer 2006; 95:1-5; PMID:16735998; http://dx.doi.org/10.1038/sj.bjc.6603201
5. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26:281-90; PMID:17603752; http://dx.doi.org/10.1007/ s10555-007-9066-y
6. Sohda M, Ishikawa H, Masuda N, Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Fukai Y, Sakurai H, et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 2004; 110:838-44; PMID:15170665; http://dx.doi.org/10.1002/ijc.20215
7. Moon SY, Chang HW, Roh JL, Kim GC, Choi SH, Lee SW, Cho KJ, Nam SY, Kim SY. Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral Oncol 2009; 45:915-9; PMID:19457706; http://dx.doi.org/10.1016/j.oraloncology. 2009.04.005
8. Staab A, Fleischer M, Loeffler J, Said HM, Katzer A, Plathow C, Einsele H, Flentje M, Vordermark D. Small interfering RNA targeting HIF-1α reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol 2011; 187:252-9; PMID:21437769; http://dx.doi.org/10.1007/s00066-011-2167-0
9. Singh IP, Mahajan S. Berberine and its derivatives: a patent review (2009 - 2012). Expert Opin Ther Pat 2013; 23:215-31; PMID:23231038; http://dx.doi.org/10.1517/13543776.2013.746314
10. Tillhon M, Guamán Ortiz LM, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol 2012; 84:1260-7; PMID:22842630; http://dx.doi.org/10.1016/j.bcp.2012.07.018
11. Hur JM, Hyun MS, Lim SY, Lee WY, Kim D. The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells. J Cell Biochem 2009; 107:955-64; PMID:19492307; http://dx.doi.org/10.1002/jcb.22198
12. Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C, Feng S, Guo H, Xu B, Yang Q, et al. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One 2011; 6:e23427; PMID:21858113; http://dx.doi.org/10.1371/journal.pone.0023427
13. Peng PL, Kuo WH, Tseng HC, Chou FP. Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys 2008; 70:529-42; PMID:18207031; http://dx.doi.org/10.1016/j.ijrobp.2007.08.034
14. Lin S, Tsai SC, Lee CC, Wang BW, Liou JY, Shyu KG. Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol Pharmacol 2004; 66:612-9; PMID:15322253
15. Hamsa TP, Kuttan G. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol 2012; 35:57-70; PMID:22145808; http://dx.doi.org/10.3109/01480545.2011.589437
16. Zhang Q, Qian Z, Pan L, Li H, Zhu H. Hypoxiainducible factor 1 mediates the anti-apoptosis of berberine in neurons during hypoxia/ischemia. Acta Physiol Hung 2012; 99:311-23; PMID:22982719; http://dx.doi.org/10.1556/APhysiol.99. 2012.3.8
17. Yoshimura M, Itasaka S, Harada H, Hiraoka M. Microenvironment and radiation therapy, Biomed Res Int (2013).
18. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33:207-14; PMID:22398146; http://dx.doi.org/10.1016/j.tips.2012.01.005
19. Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 2012; 3:783; PMID:22510688; http://dx.doi.org/10.1038/ncomms1786
20. Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 2012; 18:5585-94; PMID:23071360; http://dx.doi.org/10.1158/1078-0432.CCR-12-0858